Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Esophageal Cancer Clinical Trial

Official title:

Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04415853
• Other study ID #: PCD-DZ650-20-001
• Status: Recruiting
• Phase: Phase 3
• Start date: January 21, 2021
• Est. completion date: November 2023

Study information

• Verified date: August 2022
• Source: Sunshine Lake Pharma Co., Ltd.
• Contact: JianMing Xu, Doctor
• Phone: 010-66939843
• Email: jmxu2003[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed at least second-line treatment and overexpressed EGFR were enrolled and randomly assigned to the experimental group and control group at a 1: 1 ratio.,who received Larotinib and the chemotherapy regimen chosen by the investigator (Irinotecan Hydrochloride Injection or Tegafur Gimeracil Oteracil Potassium Capsule),respecitively. Subjects are administered until disease progression assessed by the RECIST V1.1 standard (unless the investigator evaluates that the subject continues to have clinical benefit from continuing treatment, the subject may be allowed to continue treatment), and begins to receive new anti-tumor treatment, unacceptable toxicity, withdrawal of informed consent, or other conditions that meet the criteria for terminating trial treatment / withdrawal from the trial. The research phase of this study is divided into pre-screening period (~ D-28), screening period (D-28 ~ D-1), treatment period, treatment end visit (± 7 days after the last dose), safety follow-up ( Until 28 ± 7 days after the last dose) and survival follow-up.

Description:

The experimental group and the control group were administered until the disease progression assessed by the RECIST V1.1 standard (unless The investigator evaluates that the subject continues to have clinical benefits, and the subject can be allowed to continue receiving treatment), start new anti-tumor therapy, unacceptable toxicity, withdraw informed consent, ect. The research phase of this study is divided into screening period, treatment period, treatment end visit, safety follow-up and survival follow-up. Subjects who have finished the screening examination and evaluation after the screening period enter the treatment period, and evaluate the efficacy. Subjects who have finished the treatment need to continue to undergo safety follow-up ; For subjects who have finished the trial treatment due to toxic reactions or other reasons, and have not observed the progression, they still need to carry out imaging evaluation according to the original frequency until the occurrence of tumor progression judged by RECIST V1.1 standard, start of new anti-tumor therapy, withdrawal of informed consent, loss of follow-up, death, or end of study, whichever occurs first; all subjects receive survival follow-up until death,lost of ,the follow-up or the study ended，whichever occurred first. PK studies: Pharmacokinetic (PK) studies are conducted only in centers with appropriate conditions. Only some subjects in the experiemtal group are required to undergo a PK study. Participate in intensive PK blood collection (8-12 cases), and participate in sparse PK blood collection (150 cases). Subjects participating in intensive PK blood collection do not participate in sparse PK blood collection. Biomarker research: Detect EGFR overexpression and amplification research on tumor tissue samples for all subjects and explore the relationship between its efficacy and changes in EGFR overexpression and amplification status before and after treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 416
• Est. completion date: November 2023
• Est. primary completion date: August 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Age:18-75 years, male or female.

2. Histologically or cytologically confirmed squamous cell carcinoma of the esophagus or advanced/metastatic disease.

3. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

4. Life expectancy of greater than 3 months.

5. Documented objective radiographic or clinical disease progression on two previous lines of standard therapy.

6. Can provide archival tumor tissue sample for biomarker analysis (such as EGFR overexpression/expansion status), biopsies are required if tissue samples cannot be provided

7. Confirmed by the central laboratory as EGFR high expression.

8. Evaluable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.

9. Ability to swallow drugs.

10. Adequate organ function.

11. Voluntarily join the study and sign informed consent ad has good compliance.

Exclusion Criteria:

1. Prior therapies with EGFR targeted drugs including EGFR antibodies.

2. Previously treated with Irinotecan and Tegafur.

3. Anthracycline, nitrosourea, and mitomycin within 6 weeks; traditional Chinese medicine for anti-tumor within 2 weeks;immune anti-tumor therapy. within 8 weeks;other anti-tumor therapies within 4 weeks before randomization.

4. Not recovered from adverse events due to a previously administered agent.

5. Have undergone major surgery within 4 weeks prior to randomization (not including diagnostic surgery) or expect major surgery during the study period.

6. Previously or currently participating in other clinical trials within 4 weeks before randomization (subjects who have entered the follow-up period are calculated based on the last use of experimental drugs or devices).

7. Received a live vaccine within 28 days before randomization or plan to receive live vaccine after enrollment.

8. Received a strong inducer or inhibitor of CYP3A4 enzyme within 1 week or received Solivudine or its structurally similar drugs within 56 days prior to randomization.

9. Simultaneously receiving any other anti-tumor treatment.

10. Has a known additional malignancy previously within the last 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin or any other tumor that has been cured?

11. Central nervous system metastasis or uncontrolled central nervous system metastasis currently in need of treatment; or confirmed central nervous system metastasis, but not stable for more than 4 weeks after anti-tumor therapy; spinal cord compression, cancerous meningitis, or meningitis.

12. Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs.

13. Having active gastrointestinal ulcer, active gastrointestinal bleeding, and perforation;

14. Risk of major bleeding or esophageal fistula;

15. Previous or present with interstitial lung disease or immunotherapy-associated pneumonia; currently suffering from drug-induced pneumonia, radiation pneumonitis requiring steroid therapy, or clinically symptomatic active pneumonia, or other moderate to severe lungs that seriously affect lung function disease

16. Active infection during the screening period (including but not limited to infection requiring intravenous drip therapy), or unexplained fever (> 38.5°C)within 2 weeks prior to randomization.

17. Has congenital or acquired immune deficiency (such as HIV infection).

18. Known active Hepatitis B or C.

19. Has any of the following diseases within the first 12 months of randomization:

myocardial infarction, coronary artery bypass grafting or peripheral artery bypass graft surgery, heart failure (NYHA III to IV), etc and unstable angina with 6 months.

20. Has thrombosis or embolism occurred within the first 12 months of randomization, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, pulmonary embolism with heparin or other similar drugs.

21. QTc interval (QTcF) corrected by Fridericia method> 470 ms; history of congenital long QT interval syndrome; any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation) Or torsion-type ventricular tachycardia); left ventricular ejection fraction (LVEF) <50%.

22. Allergies or contraindications to Z650 excipients (mannitol, sodium carboxymethyl starch, micronized silica gel, magnesium stearate, silicified microcrystalline cellulose), or to Irinotecan or Tegafur or its formulation ingredients.

23. Has uncontrolled pleural effusion, pericardial effusion, pelvic effusion, or ascites requiring repeated drainage.

24. Has a history of organ transplantation or a history of allogeneic bone marrow transplantation.

25. Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 6 months after the last dose of study medication.

26. Has other serious acute or chronic diseases and are not suitable for participating in clinical trials judged by investigators.

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms

Intervention

Drug:
• Lerotinib
Specification: 50 mg/capsule and 150 mg/capsule
• Irinotecan/Tegafur
Irinotecan:Specification: 2mL: 40mg;5mL:0.1g Tegafur:20mg/capsule

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Sunshine Lake Pharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Defined as time from date of randomization to date of death due to any cause. OS was calculated using product-limit (Kaplan-Meier) method for censored data.	up to approximately 22 months
Secondary	Progression-free survival	defined as the time from date of randomization until the earliest date of disease progression, as determined by independent central review of objective radiographic disease assessments per RECIST 1.1, or death from any cause, whichever comes first.	up to approximately 22 months
Secondary	Objective response rate	Objective response rate (ORR) is defined as the percentage of the participants in the analysis population who have a confirmed complete response (CR) or partial response (PR) based on RECIST 1.1 by investigators	up to approximately 22 months
Secondary	Duration of response	Defined as the time from the earliest date of qualifying response until earliest date of disease progression, per RECIST v1.1, or death from any cause, whichever comes first. Includes participants with complete response or partial response	up to approximately 22 months
Secondary	Changes in health-related quality of life with esophageal cancer symptom scale	To evaluate changes in health-related quality of life in patients with advanced esophageal cancer according to the Questionnaire	up to approximately 22 months
Secondary	Incidence of Treatment-Emergent Adverse Events	Assessed by Percentage of Participants With Adverse Events during the treatment assessed by NCI CTCAE 5.0	up to approximately 22 months
Secondary	Apparent Oral Clearance (CL/F) of Lerotinib	Defined as oral dose clearance	up to approximately 22 months
Secondary	Apparent Volume of Distribution (Vd/F) of Lerotinib	Apparent volume of distribution after administration.	up to approximately 22 months